CD8A and graft versus host disease: CD8+CD45RClow/− Tregs could, in a dose-dependent manner, inhibit GVHD and skin graft rejection indefinitely for some of the recipients, suggesting even inhibition of chronic graft rejection and a high potential for CD8+ Tregs cell-based therapy.